Nebenwirkungen · Busulfan Fresenius Kabi
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-130017 · Präparat HOS-096825
The treatment-related mortality/non-relapse mortality (TRM/NRM) reported until day+100 post- transplant has also been examined through a review of published data from clinical trials. It was considered as deaths that could be attributable to secondary side effects after HPCT and not related to the relapse/progression of the underlying haematological malignancies. The most frequent causes of reported TRM/NRMs were infection/sepsis, GVHD, pulmonary disorders and organ failure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-01T12:05:00Z · SHA-256 803007b850189812dae1406bc9fec1c869aaeaaacf0104c26b1fa84613ab3fe2 · Passage 85ff34eb55a889911e72d84307275135e914f94095af891d579effcca4201436 · Zeichen 5533–6012 im Abschnitt